Skip to main content
. Author manuscript; available in PMC: 2014 Sep 11.
Published in final edited form as: Cochrane Database Syst Rev. 2010 Oct 6;(10):CD008039. doi: 10.1002/14651858.CD008039.pub2
Study ID Treatment Nausea Vomitting Photophobia Phonophobia Functional disability
Any at 2h Relief at 2h Any at 2h Relief at 2h Any at 2h Relief at 2h Any at 2h Relief at 2h Any at 2h Relief at 2h
Codispoti 2001 (1) Ibuprofen 200 mg, n = 216

(2) Ibuprofen 400 mg, n = 223

(3) Placebo, n = 221		 (1) 77/215

(2) 72/223

(3) 84/221		 (1) 51/128

(2) 50/122

(3) 38/122		 No usable data No usable data (1) 165/216

(2) 172/223

(3) 180/221		 (1) 45/210

(2) 38/210

(3) 32/212		 (1) 151/216

(2) 156/223

(3) 170/221		 (1) 47/198

(2) 50/206

(3) 34/204		 (1) 165/216

(2) 179/223

(3) 183/221		 (1) 44/209

(2) 39/218

(3) 27/210
Diener 2004 (1) Ibuprofen 400 mg, n = 212

(2) Aspirin 1000 mg, n = 222

(3) Sumatriptan 50 mg, n = 226

(4) Placebo, n = 222		 No usable data No usable data (1) 1/212

(2) 2/222

(3) 9/226

(4) 3/222		 (1) 32/33

(2) 33/35

(3) 30/39

(4) 30/33		 (1) 49/212

(2) 56/222

(3) 44/226

(4) 70/222		 (1) 92/141

(2) 90/146

(3) 104/148

(4) 68/138		 (1) 38/212

(2) 47/222

(3) 43/226

(4) 69/222		 (1) 86/124

(2) 83/130

(3) 86/129

(4) 59/128		 No data No data
Ellis 1993 (1) Ibuprofen 600 mg + IV placebo, n = 10

(2) Placebo tablet + IV placebo, n = 10

(3) Ibuprofen 600 mg + metoclopramide 1 mg, n = 10

(4) Placebo tablet + IV metoclopramide 1 mg, n = 10		 No data
Goldstein 2006 (1) Ibuprofen 400 mg, n = 669

(2) Paracetamol/aspirin/caffeine 500/500/130 mg, n = 669

(3) Placebo, n = 221		 Proportion of participants free of migraine-associated symptoms (functional disability, nausea, photophobia and phonophobia) significantly higher for ibuprofen than placebo at most time points
Kellstein 2001 (1) Ibuprofen liquigel 200 mg, n = 198

(2) Ibuprofen liquigel 400 mg, n = 191

(3) Ibuprofen liquigel 600 mg, n = 198

(4) Placebo, n = 142		 (1) 42/198

(2) 34/191

(3) 50/198

(4) 41/143		 (1) 64/106

(2) 55/89

(3) 59/109

(4) 32/73		 No data No data (1) 134/198

(2) 113/191

(3) 120/198

(4) 108/142		 (1) 57/191

(2) 74/187

(3) 74/194

(4) 30/138		 (1) 122/198

(2) 111/191

(3) 116/198

(4) 100/142		 (1) 66/188

(2) 68/179

(3) 75/191

(4) 34/134		 > mild
(1) 54/198

(2) 45/191

(3) 53/198

(4) 64/142		 (1) 143/197

(2) 139/184

(3) 140/193

(4) 77/141
Misra 2004 (1) Ibuprofen 400 mg, n = 40

(2) Rofecoxib 25 mg, n = 42

(3) Placebo, n = 42		 No usable data: ~90% of participants had associated symptoms at baseline. Significantly more participants had relief of associated symptoms with ibuprofen 400 mg (~50%) and rofecoxib 25 mg (~40%) than placebo (~10%) No data No data
Misra 2007 (1) Ibuprofen 400 mg, n = 55

(2) Rizatriptan 10 mg, n = 57

(3) Placebo, n = 53		 Significant mean improvement in associated symptoms and functional disability with ibuprofen 400 mg compared to placebo at 2 hours
Sandrini 1998 (1) Ibuprofen arginine 400 mg, n = 34

(2) Placebo, n = 34		 No data
Saper 2006 Ibuprofen 400 mg, n = 199

Rofecoxib 25 mg, n = 194

Rofecoxib 50 mg, n = 196

Placebo, n = 194		 (1) 52/189

(2) 58/187

(3) 56/188

(4) 79/187		 (1) 65/117

(2) 51/109

(3) 73/129

(4) 32/111		 (1) 3/189

(2) 5/187

(3) 11/188

(4) 14/187		 (1) 8/11

(2) 7/12

(3) 3/14

(4) 0/187* 		(1) 95/189

(2) 96/187

(3) 93/188

(4) 122/187		 (1) 56/151

(2) 60/156

(3) 58/151

(4) 29/151		 (1) 73/189

(2) 81/187

(3) 80/188

(4) 111/187		 (1) 70/143

(2) 50/131

(3) 62/142

(4) 32/143		 (1) 114/189

(2) 119/187

(3) 120/188

(4) 155/187		 (1) 67/181

(2) 61/180

(3) 63/183

(4) 25/180**
*

Increase of 4 participants with vomiting between baseline and 2 hours

**

Increase of 3 participants with severe functional disability between baseline and 2 hours